Brussels, Belgium

Anne Rouchaud

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: University of Florida Research Foundation Inc., University of Pennsylvania. Active years: 2016.


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Anne Rouchaud: Innovator in Nicotine Compounds

Introduction

Anne Rouchaud is a notable inventor based in Brussels, Belgium. She has made significant contributions to the field of nicotine compounds and their applications. Her work focuses on the synthesis and use of various nicotine analogs, which have potential therapeutic benefits.

Latest Patents

Anne Rouchaud holds a patent for "Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use." This patent includes embodiments that provide for compounds such as 2'substituted nicotine compounds, azetidine compounds, and ether-linked nicotine compounds. The methods described in her patent involve the synthesis of these compounds and their use in treating conditions by selectively stimulating alpha7 nAChR and/or alpha4beta2 receptors.

Career Highlights

Throughout her career, Anne Rouchaud has worked with prestigious institutions, including the University of Florida Research Foundation Inc and the University of Pennsylvania. Her research has contributed to advancements in the understanding and application of nicotine-related compounds.

Collaborations

Anne has collaborated with notable individuals in her field, including William Reade Kem and Ferenc Soti. These collaborations have further enriched her research and innovation in nicotine compounds.

Conclusion

Anne Rouchaud is a pioneering inventor whose work on nicotine compounds has the potential to impact therapeutic practices. Her contributions to the field are significant and continue to inspire further research and innovation.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…